Allogeneic graft-versus-tumor effects: Mechanistic insights and therapeutic promise

Citations of this article
Mendeley users who have this article in their library.
Get full text


Cellular and molecular mechanisms of allogeneic graft-versus-tumor (GVT) effects include Th1 and Tc1 cell interleukin-2 (IL-2) and interferon-γ (IFN-γ) secretion, antigen-presenting cell (APC) IL-1-α and tumor necrosis factor-α (TNF-α) secretion, and cytolytic effectors operating through perforin, fas and TNF-related apoptosis inducing ligand (TRAIL) pathways. Because such mechanisms also contribute to graft-versus-host disease (GVHD), separation of GVT effects from GVHD has proven problematic. Research advances in allograft T cell engineering and cytokine, vaccine and molecularly targeted therapy hold promise for improved harnessing of GVT effects. © 2005 Elsevier Ltd. All rights reserved.




Fowler, D. H., & Gress, R. E. (2005). Allogeneic graft-versus-tumor effects: Mechanistic insights and therapeutic promise. Drug Discovery Today: Disease Mechanisms.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free